Price, purchasing channels and cost-effectiveness analysis of acalatinib

Acalabrutinib (also known as Acalabrutinib) is a new generation BTK inhibitor, mainly used to treat hematological tumors such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The drug is currently on the market in China and has been successfully included in the national medical insurance directory. This is a major benefit for the majority of patients, which means that they can obtain highly effective targeted therapy drugs with the support of medical insurance. Domestic hospital pharmacies have gradually been able to provide this drug. It is recommended that patients consult their attending doctors and local hospital pharmacies for specific purchase procedures and medical insurance policies before taking the drug.

In terms of price, the domestic original drug of acotinib is priced relatively high, with a box of more than 20,000 yuan. Although the actual burden on patients has decreased after medical insurance reimbursement, it is still a considerable expense for many families. The reimbursement ratio of medical insurance varies according to regional policies, but is generally around 70%, and the out-of-pocket amount is still around several thousand yuan. For hematological cancer patients who take long-term medication, this continuous expenditure can easily cause financial pressure, so many people will consider overseas generic versions with more competitive prices.

In overseas markets, the Lao version of acotinib has become an alternative choice for many patients. The specifications and ingredients of this version are basically the same as the original drug. The quality and efficacy have shown good performance in multiple clinical feedbacks, and the price is affordable. One box (common specifications) costs about more than 3,000 yuan, which has significant advantages over domestic original drugs. Although it is not covered by medical insurance, the overall cost is far lower than the domestic price, which is especially suitable for long-term treatment people with greater financial pressure.

In terms of cost performance, the Laotian generic version of acotinib has attracted more and more attention from patients due to its lower price and good treatment feedback. However, since generic drugs are purchased through overseas channels, patients should ensure that they go through formal channels when choosing to avoid buying fake or inferior drugs. Taken together, for patients with reasonable financial conditions and supported by medical insurance policies, domestic original drugs can ensure medication safety and medical security; while for patients who need long-term medication and have insufficient medical insurance coverage, Laotian generic drugs provide a more economical and affordable solution.

Reference materials:https://www.calquence.com/